HKPD vs HIMS

For growth investors, Hims & Hers Health, Inc.

(HIMS) is the stronger pick with 59. 0% revenue growth year-over-year, versus 21. 7% for Hong Kong Pharma Digital Technology Holdings Limited (HKPD). Hims & Hers Health, Inc. (HIMS) offers the better valuation at 52. 7x trailing P/E (53. 9x forward), making it the more compelling value choice. Analysts rate Hims & Hers Health, Inc. (HIMS) a "Hold" — based on 19 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Hims & Hers Health, Inc.

(HIMS) delivered a total return of +150. 5%, compared to -77. 0% for Hong Kong Pharma Digital Technology Holdings Limited (HKPD). Over 10 years, the gap is even starker: HIMS returned +174. 3% versus HKPD's -77. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Hong Kong Pharma Digital Technology Holdings Limited (HKPD) is the lower-risk stock at 1.

66β versus Hims & Hers Health, Inc. 's 2. 40β — meaning HIMS is approximately 44% more volatile than HKPD relative to the S&P 500. On balance sheet safety, Hong Kong Pharma Digital Technology Holdings Limited (HKPD) carries a lower debt/equity ratio of 48% versus 2% for Hims & Hers Health, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Hims & Hers Health, Inc.

(HIMS) is pulling ahead at 59. 0% versus 21. 7% for Hong Kong Pharma Digital Technology Holdings Limited (HKPD). On earnings-per-share growth, the picture is similar: Hims & Hers Health, Inc. grew EPS -3. 8% year-over-year, compared to -101. 7% for Hong Kong Pharma Digital Technology Holdings Limited. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Hims & Hers Health, Inc.

(HIMS) is the more profitable company, earning 5. 5% net margin versus -0. 1% for Hong Kong Pharma Digital Technology Holdings Limited — meaning it keeps 5. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: HIMS leads at 5. 2% versus 0. 7% for HKPD. At the gross margin level — before operating expenses — HIMS leads at 59. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Hong Kong Pharma Digital Technology Holdings Limited (HKPD) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding.

Hims & Hers Health, Inc. (HIMS) carries a higher beta of 2. 40 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (HKPD: -77. 0%, HIMS: +174. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (HKPD (Industrials) and HIMS (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.